PDS Biotechnology financials
$0.7429−3.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$31.5M | -$36.3M | -$43.0M | -$41.7M | -$21.4M | -$14.9M | -$21.0M |
| Net income | -$34.5M | -$37.6M | -$42.9M | -$40.9M | -$16.9M | -$14.8M | -$7.0M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 | $-0.89 | $-1.44 |
| EBITDA | -$31.5M | -$36.3M | -$43.0M | -$41.6M | -$21.4M | -$14.9M | -$17.0M |
| Operating cash flow | -$27.8M | -$35.0M | -$33.6M | -$25.7M | -$12.5M | -$13.1M | -$18.1M |
| Free cash flow | -$27.8M | -$35.1M | -$33.6M | -$25.7M | — | — | — |
| Diluted shares | 46.4M | 36.5M | 31.0M | 28.6M | 25.6M | 16.7M | 4.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.7M | $41.7M | $56.6M | $73.8M | $65.2M | $28.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $16.9M | $21.8M | $23.7M | $23.2M | $0.00 | $0.00 |
| Total assets | $30.5M | $45.4M | $59.4M | $77.0M | $67.2M | $30.9M |
| Total liabilities | $21.2M | $26.4M | $33.3M | $33.0M | $4.0M | $3.8M |
| Shareholders' equity | $9.3M | $19.0M | $26.1M | $44.0M | $63.2M | $27.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology